Clinical trials: Neuroepithelial Tumor
Medulloblastoma
Targeting MYC in High-Risk Medulloblastoma
Medulloblastoma is the most common malignant brain tumor in children. Group 3 medulloblastoma (G3 MB) represents the most aggressive molecular subtype and is associated with poor prognosis, particularly in cases characterized by…
- Trial name
- MYCMB (NCT07694622)
- Testing
- Tumor tissue collection
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Glioma
Glioma Brain Tumours - E12513 - SensiScreen Glioma
Validation of a new platform for the molecular characterization of patients affected by glioma. The new platform includes a series of faster, less expensive real-time PCR methodologies that, in comparison to standard analyses…
- Trial name
- NCT04539431
- Testing
- validation of new technologies
- Where
- Switzerland
- Volunteers
- 220 people
- Sponsor
- Ente Ospedaliero Cantonale, Bellinzona
Glioblastoma
Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma
This study is a prospective, multi-center, randomized controlled clinical study. Indications: Glioblastoma diagnosed after surgery (WHO grade IV).
- Trial name
- NCT04829097
- Testing
- Temozolomide
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Brain Tumors
Establishment of a Signature of Circulating microRNA as a Tool to Aid Diagnosis of Primary Brain Tumors in Adults
MIRNA is a prospective multi-center observational study designed to explore 762 plasma microRNAs in patients with malignant CNS tumours: 60 primary glioblastoma (GBM), 20 primary CNS lymphomas and 40 brain metastases in an…
- Trial name
- MIRNA (NCT03630861)
- Where
- France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cytomegalovirus Positive, Glioblastoma
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
This phase I/II trial studies the side effects and best dose of autologous cytomegalovirus (CMV)-specific cytotoxic T cells when given together with temozolomide and to see how well they work in treating patients with…
- Conditions
- Cytomegalovirus Positive, Glioblastoma, Gliosarcoma, Malignant Glioma
- Trial name
- NCT02661282
- Testing
- Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes, Laboratory Biomarker Analysis, Temozolomide
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma
Enhanced Adjuvant Therapy for Newly Diagnosed GBM With Partial Surgical Resection or Short-term Progression
This study is a prospective Bayesian adaptive randomized phase II clinical trial of enhanced adjuvant therapy for newly diagnosed glioblastoma with partial surgical resection or short-term progression.
- Trial name
- NCT06936046
- Testing
- Dual antibody A, Dual antibody B, Modified Stupp
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
NEUROBLASTOMA
Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement
The purposes of this study are: 1. To find the highest dose of monthly intravenous Zometa that can be given with daily low doses of cyclophosphamide by mouth to children with recurrent or refractory neuroblastoma without causing…
- Trial name
- NCT00206388
- Testing
- Zolendric acid, Cyclophosphamide
- Where
- 8 sites in United States
- Volunteers
- 21 people
- Sponsor
- Baylor College of Medicine
Glioblastoma
Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma
Part 1 (dose escalation, safety, and preliminary efficacy) Part 1 is a non-randomised, single-arm design in 12 participants with recurrent GBM suitable for maximal safe surgical resection.
- Trial name
- OPTICAL (NCT07356973)
- Testing
- irinotecan-ChemoSeed implementation into the resection cavity after surgical resection of GBM
- Where
- United Kingdom
- Volunteers
- 147 people
- Sponsor
- CRISM Therapeutics LTD
Adult Anaplastic Astrocytoma, Adult Diffuse Astrocytoma
Sunitinib in Treating Patients With Recurrent Malignant Gliomas
This phase II trial is studying how well sunitinib works in treating patients with recurrent malignant gliomas. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT00499473
- Testing
- sunitinib malate, pharmacological study
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. External-beam radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00053183
- Testing
- conventional surgery, brachytherapy, radiation therapy
- Where
- 10 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Glioma, Glioma (Diagnosis)
GliomaAI-MG: MRI-Based Detection of Molecular Glioblastoma
The goal of this observational study is to learn whether an artificial intelligence system called GliomaAI-MG can help detect a specific molecular type of brain tumour called molecular glioblastoma using routine MRI scans.
- Conditions
- Glioma, Glioma (Diagnosis), Glioblastom WHO Grade 4
- Trial name
- GliomaAI-MG (NCT07664254)
- Testing
- GliomaAI-MG
- Where
- India
- Volunteers
- 1,372 people
- Sponsor
- Deep Learning Institute of Radiological Sciences
Relapsed Cancer, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma
Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol).
- Trial name
- GBrecurr (NCT06430424)
- Testing
- Relapsed glioblastoma
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Bordeaux
Neuroblastoma
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multiple 4SCAR-T cell therapy which targets GD2, PSMA and CD276 surface antigens in patients with relapsed and refractory neuroblastoma (NB).
- Trial name
- NCT04637503
- Testing
- GD2, PSMA and CD276 CAR-T cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Brain (Nervous System) Cancers, Glioma
Connectome-guided Onco-functional Resection With Tractography-Extended Neuronavigation in Brain Tumor Surgery
Brain tumor surgery in so-called "eloquent" brain areas aims to remove as much tumor as possible while preserving neurological functions.
- Conditions
- Brain (Nervous System) Cancers, Glioma, Brain Metastasases, Brain Connectivity
- Trial name
- CORTEx (NCT07717827)
- Testing
- Connectome-guided network-based neuronavigation, Advanced diffusion MRI tractography and connectome pipeline
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- ARNAS Civico Di Cristina Benfratelli Hospital
Brain and Central Nervous System Tumors
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00498927
- Testing
- temozolomide, protein expression analysis, reverse transcriptase-polymerase chain reaction
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
RATIONALE: Ondansetron may help lessen or prevent nausea and vomiting in patients undergoing stem cell transplant. PURPOSE: This phase II trial is studying how well ondansetron works in preventing nausea and vomiting in patients…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00795769
- Testing
- ondansetron, survey administration, management of therapy complications
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Fred Hutchinson Cancer Center
Brain Tumors, Spinal Cord Tumors
Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
The goal of this clinical research study is to learn if lapatinib when given in combination with temozolomide can help to control ependymoma that has come back after treatment. The safety of this combination will also be studied.
- Trial name
- NCT00826241
- Testing
- Temozolomide, Lapatinib
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Glioblastoma, Anaplastic Astrocytoma
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in newly diagnosed glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA).
- Trial name
- NCT03603405
- Testing
- ADV/HSV-tk (gene therapy)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- The Methodist Hospital Research Institute
Neuroblastoma
A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.
This study is a multicenter, open label phase I dose escalation trial designed to define the Maximum Tolerated Dose (MTD) of 177Lu-DOTATATE in children with refractory or recurrent neuroblastoma.
- Trial name
- NEUROBLU 02 (NCT03966651)
- Testing
- PRRT with 177Lu-DOTATATE
- Where
- 14 sites in France
- Volunteers
- 1 people
- Sponsor
- Institut Claudius Regaud
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors
This pilot phase II trial is studying the side effects and best dose of erlotinib when given with temozolomide and radiation therapy and to see how well they work in treating patients with glioblastoma multiforme or other brain…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00039494
- Testing
- erlotinib hydrochloride, 3-dimensional conformal radiation therapy, temozolomide
- Where
- 139 sites in United States
- Volunteers
- 171 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.